Possibilities of therapeutic correction of ENT pathology associated with COVID-19 in children on an outpatient basis

Golovacheva E.G.; Afanasyeva O.I.; Goncharova E.S.; Bykovskaya A.G.; Davletgareeva D.V.; Apryatina V.A.

doi:https://doi.org/10.17116/otorino20218606169

Golovacheva E.G.

Smorodintsev Research Institute of Influenza

Afanasyeva O.I.

Smorodintsev Research Institute of Influenza

Goncharova E.S.

Smorodintsev Research Institute of Influenza

Bykovskaya A.G.

City Polyclinic No.106

Davletgareeva D.V.

City Polyclinic No.106

Apryatina V.A.

Saint Petersburg Institute of Bioregulation and Gerontology

ORCID: 0000-0002-9819-6835

Possibilities of therapeutic correction of ENT pathology associated with COVID-19 in children on an outpatient basis

Authors:

Golovacheva E.G., Afanasyeva O.I., Goncharova E.S., Bykovskaya A.G., Davletgareeva D.V., Apryatina V.A.

More about the authors

Journal: Russian Bulletin of Otorhinolaryngology. 2021;86(6): 69‑73

DOI: 10.17116/otorino20218606169

Read: 3318 times

To cite this article:

Golovacheva EG, Afanasyeva OI, Goncharova ES, Bykovskaya AG, Davletgareeva DV, Apryatina VA. Possibilities of therapeutic correction of ENT pathology associated with COVID-19 in children on an outpatient basis. Russian Bulletin of Otorhinolaryngology. 2021;86(6):69‑73. (In Russ., In Engl.)
https://doi.org/10.17116/otorino20218606169

Подписка 2026 Вестник оториноларингологии (Russian Bulletin of Otorhinolaryngology)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To evaluate the therapeutic and preventive efficacy of the drug with antiviral and immunotropic activity Cytovir-3 in children with COVID-19 on an outpatient basis.

MATERIAL AND METHODS

A retrospective analysis the treatment of 52 pediatric patients aged 1 to 17 years with a confirmed new coronavirus infection SARS-CoV-2 with the drug Cytovir-3 was carried out. 28 people, contacts in the family, received the drug for prophylactic purposes. Clinical observation of patients was carried out with an assessment of the severity and duration of fever, the anosmia, catarrhal symptoms in the nasopharynx and analysis indicator of saturation. In the control group, there were 27 patients of the same age who received the medicine Umifenovir and 25 contact family members who did not receive the medicine for prophylactic purposes.

RESULTS

The use of Cytovir-3 in the COVID-19 treatment in children led to a decrease in intoxication symptoms 3.2-3.4 days after taking the medicine, a significant reduction of anosmia period recovery time, and elimination of the pathogen according to PCR analysis. The patients receiving the drug did not have ENT- complications and did not require hospitalization. Prophylactic administration of the drug in contact family members statistically significantly reduced the likelihood of developing the disease 3.6 times. The clinical efficacy and feasibility of using Cytovir-3 in the treatment and prevention of new coronavirus infection in patients of different ages has been shown.

Keywords:

COVID-19

children

anosmia

Cytovir-3

outpatient treatment

Authors:

Golovacheva E.G.

Smorodintsev Research Institute of Influenza

Afanasyeva O.I.

Smorodintsev Research Institute of Influenza

Goncharova E.S.

Smorodintsev Research Institute of Influenza

Bykovskaya A.G.

City Polyclinic No.106

Davletgareeva D.V.

City Polyclinic No.106

Apryatina V.A.

Saint Petersburg Institute of Bioregulation and Gerontology

ORCID: 0000-0002-9819-6835

Received:

08.11.2021

Accepted:

06.12.2021

Close metadata

References:

Walsh KA, Spillane S, Comber L, Cardwell K, Harrington P, Connell J, Teljeur C, Broderick N, de Gascun CF, Smith SM, Ryan M, O’Neill M. The duration of infectiousness of individuals infected with SARS-CoV-2. The Journal of Infection. 2020;81(6):847-856. https://doi.org/10.1016/j.jinf.2020.10.009
Kuznik BI, Sturov VG. Features of the course of a new coronavirus infection (SARS-CoV-2) in children. Pediatriya. Zhurnal im. G.N. Speranskogo. 2020;99(6):199-208. (In Russ.). https://doi.org/10.24110/0031-403X-2020-99-6-199-208
Moein ST, Hashemian SMR, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell dysfunction: A biomarker for COVID-19. International Forum of Allergy and Rhinology. 2020; 10(8): 944-950. https://doi.org/10.1002/alr.22587
Shakmaeva MA, Chernova TM, Timchenko VN, Nachinkina TA, Tetyushin KV, Kaplina TA, Subbotina MD, Bulina OV, Afanasyeva OI. Features of a new Coronavirus infection in children of different ages. Detskie infektsii. 2021;20(2):5-9. (In Russ.). https://doi.org/10.22627/2072-8107-2021-20-2-5-9
Metodicheskie rekomendatsii. Osobennosti klinicheskikh proyavlenij i lecheniya zabolevaniya, vyzvannogo novoj koronavirusnoj infektsiej (COVID-19) u detej. Versiya 2 (03.07.2020). Ministerstvo zdravookhraneniya Rossijskoj Federatsii. (In Russ). Accessed November 25, 2021. https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/050/914/original/03062020_%D0%B4%D0%B5%D1%82%D0%B8_COVID-19_v2.pdf
Ruleva AA, Popova VV, Lyovina AV, Krasnov AA, Petlenko SV. Immunological mechanisms of the drug Cytovir®-3 action as the basis of the prevention of acute respiratory viral infections and influenza. Immunologiya. 2021;42(2):148-158. (In Russ.). https://doi.org/10.33029/0206-4952-2021-42-2-148-158
Golovacheva EG, Afanasyeva OI, Popova VV, Krasnov AA, Levina AV, Apryatina VA, Petlenko SV. Investigation of the parameters of the immune system in the prevention of acute respiratory viral infections with a drug with antiviral and immunotropic activity in healthy volunteers. RMZh. 2021;29(4):17-21. (In Russ). Accessed November 25, 2021. https://www.elibrary.ru/item.asp?id=45804455
Smirnov VS, Totolian AA. Some opportunities for immunotherapy in coronavirus infection. Russian Journal of Infection and Immunity. 2020;10(3):446-458. (In Russ.). https://doi.org/10.15789/2220-7619-SPO-1470
Smirnov VS, Leneva IA, Kudryavtseva TA, Fayzuloev EB, Zaplutanov VA, Petlenko SV, Kartashova NP, Gracheva AV, Korchevaya ER. Possibilities of suppressing the cytopathogenic effect of SARS-CoV-2 coronavirus according to the results of the antiviral activity of Cytovir®-3 in vitro study. Antibiotics and Chemotherapy. 2021;66(5-6):4-10. (In Russ.). https://doi.org/10.37489/0235-2990-2021-66-5-6-4-10
Petlenko SV, Smirnov VS, Rudenko VV. Course of intrahospital coronavirus infection (COVID-19) against the background of preventive and curative administration of peptide immunotropic drugs as part of complex therapy. Formuly farmatsii. 2020;2(3):8-13. https://doi.org/10.17816/phf43135
Smirnov VS, Petlenko SV, Osidak LV, Stukan NI, Lyovina AV, Malakhova EA, Meshkova ME. Comparative clinical and laboratory evaluation of various drugs for etiopathogenetic therapy in influenza and acute respiratory viral infections. Rossijskij immunologicheskij zhurnal. 2017;11(2/20):230-231. (In Russ.).
Karapetyan LS, Svistushkin VM. Olfactory dysfunction and COVID-19 — current state of the problem. Vestnik otorinolaringologii. 2020;85(6):100-104. (In Russ). https://doi.org/10.17116/otorino202085061100
Dondurey EA, Obraztsova EV, Semiletko YuS, Ovchinnikova NV, Golovacheva EG, Osidak LV, Afanasyeva OI. ARVI antiviral therapy in children in modern clinical practice. Medical Council. 2019;(2):183-187. (In Russ.). https://doi.org/10.21518/2079-701X-2019-2-183-187.